Logo image of ARX

ACCELERANT HOLDINGS-CL A (ARX) Stock Fundamental Analysis

USA - NYSE:ARX - KYG008941083 - Common Stock

16.47 USD
-0.48 (-2.83%)
Last: 9/17/2025, 8:23:58 PM
16.5 USD
+0.03 (+0.18%)
After Hours: 9/17/2025, 8:23:58 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ARX. ARX was compared to 146 industry peers in the Insurance industry. Both the profitability and financial health of ARX have multiple concerns. ARX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ARX was profitable.
ARX Yearly Net Income VS EBIT VS OCF VS FCFARX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

ARX has a worse Return On Assets (0.57%) than 66.44% of its industry peers.
ARX has a Return On Equity (9.43%) which is comparable to the rest of the industry.
ARX's Return On Invested Capital of 1.01% is in line compared to the rest of the industry. ARX outperforms 40.41% of its industry peers.
Industry RankSector Rank
ROA 0.57%
ROE 9.43%
ROIC 1.01%
ROA(3y)-1.68%
ROA(5y)N/A
ROE(3y)-11.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARX Yearly ROA, ROE, ROICARX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -10 -20

1.3 Margins

ARX's Profit Margin of 4.34% is on the low side compared to the rest of the industry. ARX is outperformed by 65.75% of its industry peers.
ARX's Operating Margin of 10.40% is in line compared to the rest of the industry. ARX outperforms 48.63% of its industry peers.
Industry RankSector Rank
OM 10.4%
PM (TTM) 4.34%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARX Yearly Profit, Operating, Gross MarginsARX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10 -20 -30 -40

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ARX is destroying value.
Compared to 1 year ago, ARX has about the same amount of shares outstanding.
ARX has a better debt/assets ratio than last year.
ARX Yearly Shares OutstandingARX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 50M 100M 150M 200M
ARX Yearly Total Debt VS Total AssetsARX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2B 4B 6B

2.2 Solvency

ARX has an Altman-Z score of 0.42. This is a bad value and indicates that ARX is not financially healthy and even has some risk of bankruptcy.
ARX has a Altman-Z score of 0.42. This is in the better half of the industry: ARX outperforms 69.86% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that ARX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.28, ARX perfoms like the industry average, outperforming 56.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z 0.42
ROIC/WACC0.12
WACC8.61%
ARX Yearly LT Debt VS Equity VS FCFARX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.12 indicates that ARX may have some problems paying its short term obligations.
ARX's Current ratio of 0.12 is fine compared to the rest of the industry. ARX outperforms 64.38% of its industry peers.
ARX has a Quick Ratio of 0.12. This is a bad value and indicates that ARX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ARX (0.12) is better than 64.38% of its industry peers.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
ARX Yearly Current Assets VS Current LiabilitesARX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 155.73% over the past year.
Looking at the last year, ARX shows a very strong growth in Revenue. The Revenue has grown by 78.63%.
EPS 1Y (TTM)155.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)78.63%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, ARX will show a very strong growth in Revenue. The Revenue will grow by 28.46% on average per year.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year56.96%
Revenue Next 2Y34.58%
Revenue Next 3Y28.46%
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
ARX Yearly Revenue VS EstimatesARX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ARX is valuated quite expensively with a Price/Earnings ratio of 82.35.
ARX's Price/Earnings ratio is rather expensive when compared to the industry. ARX is more expensive than 82.88% of the companies in the same industry.
When comparing the Price/Earnings ratio of ARX to the average of the S&P500 Index (27.20), we can say ARX is valued expensively.
Industry RankSector Rank
PE 82.35
Fwd PE N/A
ARX Price Earnings VS Forward Price EarningsARX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

ARX's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. ARX is more expensive than 62.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.83
ARX Per share dataARX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACCELERANT HOLDINGS-CL A

NYSE:ARX (9/17/2025, 8:23:58 PM)

After market: 16.5 +0.03 (+0.18%)

16.47

-0.48 (-2.83%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)08-28 2025-08-28/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change0%
Ins Owners25.63%
Ins Owner Change100%
Market Cap3.62B
Analysts75.71
Price Target28.11 (70.67%)
Short Float %1.84%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 82.35
Fwd PE N/A
P/S 3.7
P/FCF N/A
P/OCF N/A
P/B 8.04
P/tB 15.26
EV/EBITDA 17.83
EPS(TTM)0.2
EY1.21%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4.45
BVpS2.05
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.57%
ROE 9.43%
ROCE 1.41%
ROIC 1.01%
ROICexc 1.26%
ROICexgc 4.43%
OM 10.4%
PM (TTM) 4.34%
GM N/A
FCFM N/A
ROA(3y)-1.68%
ROA(5y)N/A
ROE(3y)-11.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA 0.99
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z 0.42
F-ScoreN/A
WACC8.61%
ROIC/WACC0.12
Cap/Depr(3y)271.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)155.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)78.63%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year56.96%
Revenue Next 2Y34.58%
Revenue Next 3Y28.46%
Revenue Next 5YN/A
EBIT growth 1Y245.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y191.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y170.93%
OCF growth 3YN/A
OCF growth 5YN/A